Methods of treating mood disorders

Abstract

Methods of treating mood disorders with compounds disclosed herein. Also provided are pharmaceutical compositions that include those compounds.

What is claimed is: 
     
         1 . A pharmaceutical composition comprising a compound represented by: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof 
       
       and a pharmaceutically acceptable adjuvant or carrier. 
     
     
         2 . (canceled) 
     
     
         3 . A method of treating a mood disorder comprising administering a therapeutically effective amount of a compound represented by: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof to a subject in need thereof. 
     
     
         4 . The method of  claim 3 , wherein the mood disorder is selected from the group consisting of depressive disorders and bipolar disorders. 
     
     
         5 . The method of  claim 3 , wherein the mood disorder is a depressive disorder. 
     
     
         6 . The method of  claim 3 , wherein the mood disorder is a treatment-resistant depressive disorder. 
     
     
         7 . The method of  claim 3 , wherein the mood disorder is selected from the group consisting of major depressive disorder, persistent depressive disorder, postpartum depression, premenstrual dysphoric disorder, seasonal affective disorder, psychotic depression, disruptive mood dysregulation disorder, substance/medication-induced depressive disorder, and depressive disorder due to another medical condition. 
     
     
         8 . The method of  claim 3 , wherein the mood disorder is selected from the group consisting of a substance-related disorder, a substance-use disorder, and an anxiety disorder. 
     
     
         9 - 10 . (canceled) 
     
     
         11 . The method of  claim 3 , wherein the mood disorder is selected from the group consisting of obsessive-compulsive and related disorders, trauma- and stressor-related disorders, feeding and eating disorders, borderline personality disorder, attention-deficit/hyperactivity disorder, and autism spectrum disorder. 
     
     
         12 . The method of  claim 3 , wherein the method comprises administering about 0.5 mg to 150 mg of the compound. 
     
     
         13 - 18 . (canceled) 
     
     
         19 . The method of  claim 3 , wherein the method provides improvement in at least one symptom selected from the group consisting of sadness or lethargy or lassitude, depressed mood, inability to feel, anxious worried feelings, fears, feeling tense, feeling restlessness, diminished interest in all or nearly all activities, difficulty initiating activities, significant increased or decreased appetite leading to weight gain or weight loss, insomnia, irritability, fatigue, feelings of worthlessness or low self-esteem, strongly held negative beliefs or pessimistic thoughts about self, others or world, feelings of helplessness, inability to concentrate or distractibility, recurrent thoughts of death or suicide, feelings of guilt, memory complaints, difficulty experiencing positive feelings, feeling cut off or distant from people, hypervigilance, risk taking behavior, avoidance of thoughts about a stressful or traumatic event, pains and aches, ruminations and obsessive thoughts, compulsive behaviors, talking to people you don't know well or strangers, being center of attention, disturbing intrusive thoughts, can't get through week without drug use, guilty about drug use, problems with friends or family due to drug use, and withdrawal symptoms due to drug use. 
     
     
         20 . (canceled) 
     
     
         21 . The method of  claim 3 , wherein the compound is administered from one to four times per day. 
     
     
         22 . (canceled) 
     
     
         23 . A method of treating a mood disorder comprising administering to a patient in need thereof a pharmaceutical composition comprising an effective amount of a compound represented by: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 
     
     
         24 . The method of  claim 23 , wherein the mood disorder is selected from the group consisting of depressive disorders and bipolar disorders. 
     
     
         25 . The method of  claim 23 , wherein the mood disorder is a depressive disorder. 
     
     
         26 . The method of  claim 23 , wherein the mood disorder is a treatment-resistant depressive disorder. 
     
     
         27 . The method of  claim 23 , wherein the mood disorder is selected from the group consisting of major depressive disorder, persistent depressive disorder, postpartum depression, premenstrual dysphoric disorder, seasonal affective disorder, psychotic depression, disruptive mood dysregulation disorder, substance/medication-induced depressive disorder, and depressive disorder due to another medical condition. 
     
     
         28 . The method of  claim 23 , wherein the mood disorder is selected from the group consisting of a substance-related disorder, a substance-use disorder, and an anxiety disorder. 
     
     
         29 - 30 . (canceled) 
     
     
         31 . The method of  claim 23 , wherein the mood disorder is selected from the group consisting of obsessive-compulsive and related disorders, trauma- and stressor-related disorders, feeding and eating disorders, borderline personality disorder, attention-deficit/hyperactivity disorder, and autism spectrum disorder. 
     
     
         32 . The method of  claim 23 , wherein the method comprises administering about 0.5 mg to 150 mg of the compound. 
     
     
         33 - 34 . (canceled) 
     
     
         35 . The method of  claim 23 , wherein the method provides improvement in at least one symptom selected from the group consisting of sadness or lethargy or lassitude, depressed mood, inability to feel, anxious worried feelings, fears, feeling tense, feeling restlessness, diminished interest in all or nearly all activities, difficulty initiating activities, significant increased or decreased appetite leading to weight gain or weight loss, insomnia, irritability, fatigue, feelings of worthlessness or low self-esteem, strongly held negative beliefs or pessimistic thoughts about self, others or world, feelings of helplessness, inability to concentrate or distractibility, recurrent thoughts of death or suicide, feelings of guilt, memory complaints, difficulty experiencing positive feelings, feeling cut off or distant from people, hypervigilance, risk taking behavior, avoidance of thoughts about a stressful or traumatic event, pains and aches, ruminations and obsessive thoughts, compulsive behaviors, talking to people you don't know well or strangers, being center of attention, disturbing intrusive thoughts, can't get through week without drug use, guilty about drug use, problems with friends or family due to drug use, and withdrawal symptoms due to drug use. 
     
     
         36 - 37 . (anceled)